# Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

> **NCT00479622** · PHASE1 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 20 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** TRU-015

## Key facts

- **NCT ID:** NCT00479622
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2008-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479622, "Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00479622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*